52 Participants Needed

PF-07905428 for Acne

Recruiting at 1 trial location
PC
Overseen ByPfizer CT.gov Call Center
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: Pfizer

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07905428) for the potential treatment of acne vulgaris.This study is seeking participants who:* Are male or female between the ages of 18 and 40* Are generally healthy* Are diagnosed with moderate to severe acne vulgaris (Cohort 4 only)The study medicine will be applied every day on the participant's face and/or back for 14 days (Cohorts 1 and 2) or for 28 days (Cohort 3 and 4).The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help the investigators determine if the study medicine is safe and effective.Participants will take part in this study for approximately 2 months. During this time, they will have 17 study visits (Cohorts 1 and 2) or 31 study visits (Cohorts 3 and 4) at the study clinic. The study team will also call participants once at the end of the study over the phone.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team to get a clear answer.

Who Is on the Research Team?

PC

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Are You a Good Fit for This Trial?

This trial is for men and women aged 18-40 who are generally healthy and have moderate to severe acne vulgaris. Participants will use the study medicine PF-07905428 or a placebo on their face/back daily for up to 28 days, with follow-up visits at the clinic.

Inclusion Criteria

I have mild to moderate acne on my face.
Participants who are overtly healthy as determined by medical evaluation
I have moderate to severe acne on my face.
See 1 more

Exclusion Criteria

Participants with autoinflammatory syndromes
I have a significant history of major health issues.
I have very severe acne.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the study medicine applied daily on the face and/or back for 14 days (Cohorts 1 and 2) or 28 days (Cohorts 3 and 4)

2-4 weeks
17 visits (Cohorts 1 and 2) or 31 visits (Cohorts 3 and 4)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks
1 call (phone)

What Are the Treatments Tested in This Trial?

Interventions

  • PF-07905428
Trial Overview The trial tests PF-07905428's safety and effectiveness against acne vulgaris compared to a placebo. It involves daily application of the medication, regular clinic visits over approximately two months, and one follow-up phone call.
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-07905428 Low StrengthExperimental Treatment1 Intervention
Group II: PF-07905428 High StrengthExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Pfizer

Lead Sponsor

Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni profile image

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security